FDA reviewing Sun's psoriasis candidate tildrakizumab
Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA accepted for review a BLA for tildrakizumab (MK-3222) to treat moderate to severe plaque psoriasis. The company declined to disclose the PDUFA date.
In March, EMA validated an MAA for the product in the indication (see BioCentury, April 3)...
BCIQ Target Profiles